go to medicines.ie homepage
Font Size
Search for:  
select
  Advanced Search

Abbott Healthcare Products Limited
2.1 Woodford Business Park, Santry, Dublin 9, Ireland
Telephone: +353 1 8468793
Fax: +353 1 8468701
Medical Information Direct Line: +44 (0)2380 467 000
Medical Information e-mail: medinfo.shl@abbott.com
Medical Information Facsimile: +44 (0)2380 467052
Summary of Product Characteristics last updated on medicines.ie: 17/08/2011
SPC Femoston-conti

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 17/08/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 3 - Pharmaceutical form
Date of revision of text on the SPC:   27-Jul-2011
Legal Category:   Product subject to medical prescription which may not be renewed (A)

Free-text change information supplied by the pharmaceutical company
In section 3, the tablet description has been updated due to the removal of the 'Solvay embossing'
Updated on 15/06/2010 and displayed until 17/08/2011
Reasons for adding or updating:
  • Change to section 6.4 - Special precautions for storage
  • Change to section 7 - Marketing authorisation holder
Date of revision of text on the SPC:   10-May-2010
Legal Category:   Product subject to medical prescription which may not be renewed (A)

Free-text change information supplied by the pharmaceutical company
The name of the Marketing Authorisation Holder has changed to Abbott Healthcare Products Ltd.
Storage instructions have been made more specific. 
Updated on 28/11/2005 and displayed until 15/06/2010
Reasons for adding or updating:
  • Change to section 1 - Name of medicinal product
Updated on 06/08/2004 and displayed until 28/11/2005
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
Updated on 27/06/2003 and displayed until 06/08/2004
Reasons for adding or updating:
  • New SPC for new product

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
  Dydrogesterone
  Estradiol Hemihydrate